Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
Publication in refereed journal

Times Cited
Web of Science8WOS source URL (as at 14/05/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractR483 is a thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist with anti-diabetic properties and also a cytochrome P450 2C19 (CYP2C19) substrate. The aim of the clinical studies reported here was to investigate the influence of the CYP2C19 genotype on the pharmacokinetics (PK) of R483 in healthy subjects and in type 2 diabetes mellitus (T2DM) patients.
All Author(s) ListBogman K, Silkey M, Chan SP, Tomlinson B, Weber C
Journal nameEuropean Journal of Clinical Pharmacology
Detailed descriptionTo ORKTS: Published online: 12 June 2010
Volume Number66
Issue Number10
PublisherSpringer Verlag (Germany)
Pages1005 - 1015
LanguagesEnglish-United Kingdom
KeywordsCYP2C19; Metabolism; Pharmacokinetics; Polymorphism; Type 2 diabetes mellitus patients
Web of Science Subject CategoriesPharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

Last updated on 2021-15-05 at 00:20